Raptiva Withdrawn from U.S. Market

Michael Roberts
Attorney
(866) 735-1102 Ext 506
Posted by Michael RobertsApril 09, 2009 2:29 PM

On April 8, the psoriasis drug Raptiva (efalizumab) was the subject of an announced phased voluntary withdrawal from the United States market. Its manufacturer, Genentech, made this announcement due to potential risk to patients of developing a severe, progressive neurologic disease known as progressive multifocal leukoencephalopathy. This disease is caused by a virus that affects the central nervous system. Raptiva will be no longer available in the U.S. after June 8, 2009.

A February 19 FDA Public Health Advisory warned of PML risks in taking Raptiva, after reports were received of PML disease in patients who had been taking Raptiva.

0 Comments

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

Comments for this article are closed.

Subscribe to InjuryBoard Gadsden

InjuryBoard Gadsden RSS Feeds

Keep up with the latest updates using your favorite RSS reader

Injury Board Gadsden is brought to you by Cusimano, Keener, Roberts, Knowles & Raley, LLC

Legal Assistance Center

More Info
Cusimano, Keener, Roberts, Knowles & Raley, LLC 866-735-1102 ext. 505 www.alabamatortlaw.com
google
Personal Injury Lawyers Serving: Gadsden, Albertville, Anniston, Ashland, Attalla, Fort Payne, Goodwater, Jacksonville, Lafayette, Oneonta, Opelika, Oxford, Pell City, Rainbow City, Roanoke, Scottsboro, Springville, Talladega
153 South Ninth Street, Gadsden, Alabama 35901 [ Show Map ]
Better Business Bureau Accredited Business Confidential

Your question will be referred to an attorney near you. If your question is of a legal nature, then by submitting this form you agree you are not forming a formal attorney / client relationship. Read our full privacy policy.

Looking for an InjuryBoard attorney closer to home? Click here.

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address